Group One Trading
SUPN icon

Group One Trading’s Supernus Pharmaceuticals SUPN Stock Holding History

Group One Trading’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$62K Sell
1,200
-5,100
-81% -$260K ﹤0.01% 5095
2025
Q4 		$313K Buy
+6,300
New +$306K ﹤0.01% 3968
2025
Q3 		– Sell
-400
Closed -$12.6K – 9117
2025
Q2 		$12.6K Sell
400
-100
-20% -$3.21K ﹤0.01% 6578
2025
Q1 		$16.4K Buy
+500
New +$17.7K ﹤0.01% 5952
2022
Q4 		– Sell
-72,500
Closed -$2.45M – 8059
2022
Q3 		$2.45M Buy
72,500
+100
+0.1% +$3.25K ﹤0.01% 1734
2022
Q2 		$2.09M Buy
72,400
+49,700
+219% +$1.42M ﹤0.01% 2016
2022
Q1 		$734K Sell
22,700
-1,300
-5% -$39.9K ﹤0.01% 3408
2021
Q4 		$700K Buy
24,000
+22,300
+1,312% +$677K ﹤0.01% 3734
2021
Q3 		$45K Sell
1,700
-400
-19% -$10.7K ﹤0.01% 6622
2021
Q2 		$65K Sell
2,100
-4,700
-69% -$144K ﹤0.01% 6351
2021
Q1 		$178K Buy
6,800
+2,800
+70% +$78.3K ﹤0.01% 5142
2020
Q4 		$101K Sell
4,000
-100
-2% -$2.15K ﹤0.01% 4555
2020
Q3 		$85K Sell
4,100
-30,900
-88% -$701K ﹤0.01% 4303
2020
Q2 		$831K Sell
35,000
-15,200
-30% -$336K ﹤0.01% 2200
2020
Q1 		$903K Sell
50,200
-98,100
-66% -$2.06M 0.01% 1602
2019
Q4 		$3.52M Buy
148,300
+7,400
+5% +$180K 0.02% 893
2019
Q3 		$3.87M Buy
140,900
+129,000
+1,084% +$3.82M 0.03% 739
2019
Q2 		$394K Sell
11,900
-10,500
-47% -$360K ﹤0.01% 2352
2019
Q1 		$785K Buy
22,400
+3,800
+20% +$141K 0.01% 1583
2018
Q4 		$618K Buy
18,600
+800
+4% +$34.4K 0.01% 1856
2018
Q3 		$896K Sell
17,800
-3,200
-15% -$158K 0.01% 1783
2018
Q2 		$1.26M Buy
21,000
+9,300
+79% +$482K 0.01% 1490
2018
Q1 		$536K Buy
11,700
+6,700
+134% +$280K 0.01% 2014
2017
Q4 		$199K Sell
5,000
-23,900
-83% -$944K ﹤0.01% 2929
2017
Q3 		$1.16M Sell
28,900
-22,900
-44% -$991K 0.01% 1448
2017
Q2 		$2.23M Buy
51,800
+11,400
+28% +$406K 0.02% 894
2017
Q1 		$1.26M Buy
40,400
+12,400
+44% +$332K 0.01% 1172
2016
Q4 		$707K Sell
28,000
-11,500
-29% -$257K 0.01% 1548
2016
Q3 		$977K Sell
39,500
-15,700
-28% -$355K 0.01% 1295
2016
Q2 		$1.12M Buy
55,200
+15,900
+40% +$282K 0.01% 1184
2016
Q1 		$599K Sell
39,300
-25,500
-39% -$333K 0.01% 1554
2015
Q4 		$871K Sell
64,800
-14,000
-18% -$217K 0.01% 1400
2015
Q3 		$1.11M Buy
78,800
+8,900
+13% +$165K 0.02% 1172
2015
Q2 		$1.19M Sell
69,900
-48,800
-41% -$695K 0.02% 1083
2015
Q1 		$1.44M Buy
118,700
+91,900
+343% +$868K 0.02% 823
2014
Q4 		$222K Sell
26,800
-4,700
-15% -$39.5K ﹤0.01% 2231
2014
Q3 		$274K Sell
31,500
-99,300
-76% -$897K ﹤0.01% 2125
2014
Q2 		$1.43M Sell
130,800
-211,400
-62% -$1.88M 0.02% 909
2014
Q1 		$3.06M Buy
342,200
+221,100
+183% +$2.04M 0.05% 418
2013
Q4 		$913K Buy
121,100
+65,800
+119% +$460K 0.01% 1174
2013
Q3 		$405K Buy
55,300
+19,500
+54% +$131K 0.01% 1795
2013
Q2 		$230K Buy
+35,800
New +$211K 0.01% 2050

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading's SUPN Position: Q1 2026 in Review

Group One Trading sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 331 shares — an estimated $16.9K sold.

Group One Trading first reported a position in SUPN in Q4 2013 and held it in 28 quarters. The position peaked at $2.95M in Q1 2014. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Group One Trading reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 331 Supernus Pharmaceuticals shares in Q1 2026, an estimated $16.9K.
  • Group One Trading first reported a position in Supernus Pharmaceuticals in Q4 2013 and held it in 28 quarters.
  • Group One Trading's Supernus Pharmaceuticals position peaked at $2.95M in Q1 2014.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.